VIDEO: Expert discusses FDA pooled analyses in lung cancer
Click Here to Manage Email Alerts
In this video, Melina Marmarelis, MD, discussed results from two FDA pooled analyses in lung cancer that were presented at the ASCO annual meeting.
“We need better indicators for what is high-risk disease in order to choose patients who could benefit from chemotherapy because clearly there’s a population that can really benefit from chemotherapy, even in the high PD-L1 group,” Marmarelis, assistant professor of medicine at the University of Pennsylvania, said.
Collapse
Healio Interviews
Akinboro O, et al. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis. Presented at: ASCO Annual meeting; June 3-7, 2022; Chicago.
Nakajima EC, et al. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. Presented at: ASCO Annual meeting; June 3-7, 2022; Chicago.
Read more about
Click Here to Manage Email Alerts